A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)

This study is testing AK112 — a new bispecific drug that targets both PD-1 (an immune checkpoint) and VEGF (a protein that promotes tumor blood vessel growth) — in patients with advanced hepatocellular carcinoma (liver cancer) that has progressed or they have not yet received treatment. **You may be eligible if...** - You have confirmed advanced liver cancer (hepatocellular carcinoma, HCC) - You are in good physical condition (ECOG 0 or 1) - You have a life expectancy of at least 3 months - For some parts of the study: your cancer has progressed after prior therapy; for others: you have not yet received systemic treatment **You may NOT be eligible if...** - You have serious liver disease that would make treatment unsafe - You are in poor physical condition - Your liver cancer does not meet imaging or biopsy diagnostic criteria - You have received treatments that exclude you from the specific phase of the study Talk to your doctor to see if this trial is right for you.